Omnicell (NASDAQ:OMCL) Releases FY 2024 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.650-1.720 for the period, compared to the consensus earnings per share estimate of 1.370. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q4 guidance to $0.55-$0.62 EPS.

Omnicell Stock Performance

Shares of Omnicell stock traded up $0.03 on Friday, hitting $48.67. The stock had a trading volume of 683,792 shares, compared to its average volume of 528,146. The company has a quick ratio of 2.22, a current ratio of 1.05 and a debt-to-equity ratio of 0.47. Omnicell has a one year low of $25.12 and a one year high of $55.74. The stock’s 50-day simple moving average is $43.26 and its two-hundred day simple moving average is $35.17.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. The business had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. During the same quarter last year, the business posted $0.29 EPS. The business’s revenue was down 7.4% on a year-over-year basis. As a group, equities analysts predict that Omnicell will post 0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

OMCL has been the topic of a number of recent research reports. Craig Hallum increased their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. lifted their target price on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Bank of America reiterated a “neutral” rating and set a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research note on Thursday. Finally, Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Omnicell currently has a consensus rating of “Hold” and an average target price of $49.14.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.